Status:

COMPLETED

A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)

Lead Sponsor:

Endo Pharmaceuticals

Conditions:

Plantar Fasciitis

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.

Eligibility Criteria

Inclusion

  • Key
  • Have no significant medical history or examination findings related to the foot to be treated, which in the investigator's opinion, would make the participant unsuitable for study intervention administration.
  • Have a diagnosis of plantar fasciitis for ≥6 months, which has not responded to conservative therapies. Conservative therapies may include rest, physical therapy, splinting/bracing, orthotics, icing, physiotherapy, acetaminophen, corticosteroids, or nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Have current foot pain due to plantar fasciitis.
  • Key

Exclusion

  • Has any musculoskeletal, neuromuscular, neurosensory, other neurological or related disorder that affects the participant's use of his/her feet and/or would impair his/her completion of study assessments as determined by the investigator either due to the disorder or due to pain.
  • Has a clinically meaningful laboratory abnormality.
  • Has a body mass index ≥35 kilograms per meter squared (kg/m\^2).
  • Has a known bleeding disorder, which, in the investigator's opinion, would make the participant unsuitable for enrollment in the study.

Key Trial Info

Start Date :

January 3 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 30 2024

Estimated Enrollment :

231 Patients enrolled

Trial Details

Trial ID

NCT06169319

Start Date

January 3 2024

End Date

September 30 2024

Last Update

September 30 2025

Active Locations (39)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (39 locations)

1

Endo Site 8

Tucson, Arizona, United States, 85712

2

Endo Site 20

Castro Valley, California, United States, 94546

3

Endo Site 13

Corona, California, United States, 92882

4

Endo Site 6

Encinitas, California, United States, 92024